This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Lenzi R , Edwards R , June C , Seiden MV , Garcia ME , Rosenblum M , Freedman RS
Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma
Journal of Translational Medicine. 2007 Dec;5 :66
AbstractBackground: Pharmacokinetic advantages of intraperitoneal (IP) rhIL-12, tumor response to IP delivery of other cytokines as well as its potential anti-angiogenic effect provided the rationale for further evaluation of IPrhIL-12 in patients with persistent ovarian or peritoneal carcinoma. Methods: A phase 2 multi-institutional trial (NCI Study # 2251) of IP rIL-12 (300 nanogram/Kg weekly) was conducted in patients with ovarian carcinoma or primary peritoneal carcinoma. Patients treated with primary therapy for ovarian cancer who had no extraabdominal/parenchymal disease or bulky peritoneal disease were eligible. Four to 8 weeks from last chemotherapy, eligible patients underwent a laparotomy/laparoscopy. Patients with residual disease <= 1 cm were registered for the treatment phase 2 - 5 weeks post surgery. The effect of IP rIL- 12 on the expression of TNF alpha, INF alpha, IL-10, IP-10, IL-8, FGF, VEGF was also studied. Results: Thirty-four patients were registered for the first screening phase of the study. Median age was 56.6 years ( range: 31 - 71); 12 completed the second phase and were evaluable for response/toxicity. Performance scores of IL-12 treated patients were 0 (11 pts) and 1 (1 pt). There were no treatment related deaths, peritonitis or significant catheter related complications. Toxicities included grade 4 neutropenia (1), grade 3 fatigue (4), headache (2), myalgia (2), non-neutropenic fever (1), drug fever (1), back pain (1), and dizziness (1). The best response observed was SD. Two patients had SD and 9 had PD, and 1 was evaluable for toxicity only. Peritoneal fluid cytokine measurements demonstrated a >= 3 fold relative increase post-rhIL-12: IFN-gamma, 5/5 pts; TNF-alpha, 1/5; IL-10, 4/5; IL-8, 5/5; and VEGF, 3/5. IP10 levels were increased in 5/5 patients. Cytokine response profiles suggest either NK or T-cell mediated effects of IP rhIL-12. Cytokine/chemokine results also suggest a pleiotropic response since proteins with potential for either anti-tumor (IFN-gamma, IP-10) or pro-tumor growth effects (VEGF, IL-8) were detected. Conclusion: IP IL-12 can safely be administered at this dose and schedule to patients after first line chemotherapy for ovarian/peritoneal carcinoma. The maximum response was stable disease. Future IP therapies with rhIL-12 will require better understanding and control of pleiotropic effects of IL-12.
NotesISI Document Delivery No.: 266UC Times Cited: 0 Cited Reference Count: 14 Cited References: *FDA, 2006, M SUMM APR 26 BEREK JS, 1985, CANCER RES, V45, P4447 DEDRICK RL, 1978, CANC TREAT REP, V62, P2 EDWARDS RP, 1997, J CLIN ONCOL, V15, P3399 GORDON IO, 2006, CLIN CANCER RES, V12, P1515 LENZI R, 2002, CLIN CANCER RES, V8, P3686 LOERCHER AE, 1999, J IMMUNOL, V163, P6251 MELICHAR B, 2003, J IMMUNOTHER, V26, P270 MELICHAR B, 2003, J TRANSL MED, V1, P5 PUJADELAURAINE E, 1996, J CLIN ONCOL, V14, P343 SGADARI C, 1996, BLOOD, V87, P3877 STEIS RG, 1990, J CLIN ONCOL, V8, P1618 VOEST EE, 1995, J NATL CANCER I, V87, P581 WILLEMSE PHB, 1990, EUR J CANCER CLIN ON, V26, P353 Lenzi, Renato Edwards, Robert June, Carl Seiden, Michael V. Garcia, Michael E. Rosenblum, Michael Freedman, Ralph S. BIOMED CENTRAL LTD; MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND